In Guangzhou, 76‑year‑old Uncle Chen, who has long battled hypertension and diabetes, suddenly fell ill with a high fever and severe cough. Doctors at Nanfang Hospital diagnosed him with influenza A and, after traditional antivirals caused stomach upset or failed to work, they tried a new home‑grown pill called onradivir. Within hours his fever dropped and his cough eased, showing how the drug – designed to hit a specific part of the flu virus – can act fast and safely, even for patients with mild kidney problems. A similar story is unfolding for stroke patients. When Ms Zhang in Jiangsu suffered a massive brain‑blood‑vessel blockage, doctors used a novel sublingual tablet, edaravone‑dexborneanol, during transport to protect her brain cells. The treatment helped her survive the critical “golden” window and recover well after surgery. These successes are part of a broader surge in Chinese pharmaceutical innovation. Since 2024, more than 200 new drugs have been approved, with domestic products now making up over 80 % of the market. Heavy R&D spending, fast‑track regulatory pathways, and strong government backing have turned China from a drug importer into a global innovator, delivering life‑saving medicines for flu, stroke, cancer and beyond.
Read moreThe 2026 European Atherosclerosis Society meeting unveiled a wave of cutting‑edge research focused on the protein PCSK9, a key driver of high cholesterol and cardiovascular disease. First, a Chinese team used computer‑aided drug design to create a peptide‑based PROTAC called Cadd4 that tags PCSK9 for destruction, offering a low‑cost, highly specific way to lower LDL cholesterol. In parallel, scientists reported an epigenetic editor that can permanently switch off the PCSK9 gene with a single injection, cutting LDL levels by up to 90 % in animal models and showing strong safety signals. Clinical data from the LIBerate‑HR trial, published in JAMA Cardiology, showed the monoclonal‑like inhibitor lerodalcibep slashing LDL by an average of 56 % in high‑risk patients, with 94 % achieving at least a 50 % reduction and sustained benefits over two years. Beyond heart disease, Nature papers linked PCSK9 to pancreatic cancer spread and to the fragility of arterial plaques by triggering ferroptosis in smooth‑muscle cells, opening new therapeutic angles. Together, these discoveries signal a new era of long‑acting, precise, and potentially curative lipid‑lowering therapies that could transform how doctors treat cholesterol, diabetes‑related heart risk, and even certain cancers.
Read moreA wave of fresh findings is reshaping how doctors treat blood‑related cancers. First, experts are re‑examining the role of radiation for primary central nervous system lymphoma, proposing it as a precise, targeted tool within combined treatment plans rather than a blanket approach. In parallel, a new consensus from the journal *Blood* offers clear guidance on using CAR‑T cell therapy for adult acute lymphoblastic leukemia, covering who should receive it, how to bridge to treatment, manage side‑effects, and evaluate outcomes. Leading Chinese hematologists also highlight recent CAR‑T successes in relapsed or refractory B‑ALL, noting impressive remission rates for patients who have run out of standard options. Researchers from Peking University examined how existing autoimmune diseases affect outcomes after stem‑cell transplants for myelodysplastic syndromes, finding that disease activity at transplant time can influence complications and survival. The European Bone Marrow Transplant (EBMT) group released practical tips for spotting and diagnosing central nervous system complications after allogeneic transplants, aiming for faster, more accurate treatment. Real‑world studies from Germany confirm that the drug ciltacabtagene is effective and safe when used earlier in relapsed/refractory multiple myeloma, mirroring trial results. Conversely, data on bispecific antibodies for B‑cell lymphoma reveal early‑onset heart toxicity that can be fatal, underscoring the need for vigilant monitoring. Genomic analyses of newly diagnosed Chinese multiple‑myeloma patients map tumor‑microenvironment interactions, uncovering new biomarkers and a risk‑stratification model tailored to this population. The ASCO Educational Book discusses smoldering myeloma, emphasizing how genetic profiling can guide early intervention. A large Asian Phase 3 trial led by Prof. Qiu Lugui shows that the targeted drug acalabrutinib matches or exceeds the traditional bendamustine‑rituximab combo for treatment‑naïve chronic lymphocytic leukemia patients unsuitable for intensive chemotherapy. Cutting‑edge laboratory work identifies the protein ZMIZ1 as a key blocker of AML cell differentiation, suggesting a novel therapeutic angle. A comprehensive review of acute lymphoblastic leukemia trends from 1990‑2021 details shifting disease burdens across ages and genders worldwide. Finally, clinicians debate the best second‑line approach for patients with refractory large B‑cell lymphoma who cannot undergo transplant, weighing CAR‑T against bispecific antibodies, and a Blood Reviews article surveys the expanding arsenal of immunotherapies—monoclonal antibodies, bispecifics, CAR‑T—being tested for acute myeloid leukemia. Together, these updates provide a clearer, more hopeful roadmap for patients and physicians navigating blood‑cancer care.
Read more